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1. Introduction 
Parkinson's disease (PD) is a degenerative disease of the central nervous system (CNS) 
predominantly occurring in older adults, and is particularly common after the age of 60. The 
primary pathologic characteristics of PD are neuronal degeneration and cell death of 
dopaminergic (DA-ergic) neurons, leading to a decrease in the dopamine (DA) level in the 
striatum. Originally extracted and purified in 1993, glial cell line-derived neurotrophic 
factor (GDNF) is a novel neurotrophic factor which exerts neurotrophic effects upon DA-
ergic neurons in the midbrain, sympathetic neurons in the superior cervical ganglion and 
motor neurons in the spinal cord. Specially, GDNF protects midbrain DA-ergic neurons, and 
promotes their differentiation and survival (Lin et al., 1993). These studies provide impetus 
to delve more deeply into the underlying mechanisms of GDNF, and suggest potential 
future applications of GDNF. The present review focuses on the correlates of neurotrophic 
factors and PD treatments, and the mechanisms of action of GDNF.    
2. Parkinson's disease and neurotrophic factors 
2.1 Parkinson's disease 
Parkinson's disease (PD) is also known as paralysis agitans. As a degenerative disease of the 
central nervous system (CNS), PD is characterized by static tremors, bradykinesia, myotonia 
and unstable posture. It is a disease normally occurring in older adults, especially after the 
age of 60. Thus far, the etiology and mechanisms underlying this disease have not been fully 
elucidated (Daly et al., 1999), though most scholars support the dopamine hypothesis and 
the oxidative stress hypothesis of PD. According to the dopamine hypothesis, dopamine 
synthesis decreases following the pathologic degeneration of DA-ergic neurons in the 
substantia nigra pars compacta (SNpc), leading to a decrease in inhibition of acetylcholine in 
the corpus striatum and a relative increasing excitability of acetylcholine. The 
disequilibrium between dopamine and acetylcholine results in the hyper-functioning of the 
extrapyramidal system, thus leading to paralysis agitans. The oxidative stress hypothesis 
explains the causes of degeneration of DA-ergic neurons in the SNpc. In PD, hydrogen 
peroxide (H2O2) and superoxide anions, produced during the process of oxidative 
metabolism under oxidative stress, are catalyzed by Fe2+ in the SNpc, and then formed into 
hydroxy radicals with more significant noxious properties. Meanwhile, the activity of 
complex I of the mitochondrial respiratory chain in DA-ergic neurons decreases, causing 
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antioxidants (esp. glutathione) to disappear. At this point, the free radicals can no longer be 
removed. Thus, by oxidizing the lipoids of neurilemma, destroying the functions of the 
membranes and directly demolishing DNA in DA-ergic neurons, the free radicals cause the 
degeneration and death of the neurons.  
2.2 Neurotrophic factors 
Neurotrophic factors (NTFs), discovered at the end of the 20th century, are dissoluble 
polypeptides derived from tissues (e.g. muscles) which are innervated by nerves, or from 
astrocytes. They can promote and maintain the growth, survival and differentiation of 
specific neurons, as well as influence synaptic plasticity. More than twenty NTFs are known 
to exist, including brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF) 
and glial cell line-derived neurotrophic factor (GDNF). Sharing as much as 50 - 60% 
homology in amino acid sequence, NTFs are quite congenerous. In general, the NTFs enter 
the nerve terminal through receptor-mediated endocytosis, then transport to the cell soma 
by retrograde axoplasmic transport. There, they promote the synthesis of numerous proteins 
supporting the growth, development and functional integrity of neurons. Recently, some 
NTFs were found to be produced by neurons and transported to nerve endings by 
anterograde axoplasmic transport, where they play a role in supporting the integrity of 
shape and function in postsynaptic neurons. 
Neurotrophic factors, especially GDNF, exert protective effects on DA-ergic neurons, 
correlating with the etiology of PD. Some studies have demonstrated that the amount of 
NTFs is decreased in PD patients, compared with control. It is highly likely that this 
decrease could lead to the degeneration and death of DA-ergic neurons and induce the 
clinical symptoms of PD. In addition, some scholars propose that the apoptosis of numerous 
neurons during the process of development may be related to a decrease in NTFs. Studies 
based on animal models have demonstrated that the application of NTFs-medium can 
increase the survival rate of fetal DA-ergic neurons and reduce apoptosis in vitro (Siegel & 
Chauhan, 2000). Currently, no evidence exists addressing whether defects of NTFs or 
decreased expression of receptors for NTFs occur during the pathogenic progress of PD. 
3. The structure, expression and basic physiological properties of GDNF 
3.1 The structure of GDNF 
The GDNF family ligands (GFLs) belong to the transforming growth factor-ǃ (TGF-ǃ) super-
family, and include four neurotrophic factors: glial cell line-derived neurotrophic factor 
(GDNF), neurturin (NRTN), artemin (ARTN) and persephin (PSPN). These factors possess 
structures similar to other factors in the TGF-ǃ super-family, and function as homodimers 
(Ibáñez, 1998). GFLs transduce signals through a receptor system, which is a protein 
complex consisting of RET tyrosine protein kinase and the GFRǂ family of proteins, playing 
an important role in the biological processes of cell survival, differentiation and migration. 
The GFLs are secretory proteins, derived from the precursor preproGFL. ProGFLs can be 
activated by proteolytic cleavage. The diffusion and local concentration of proGFLs are 
influenced by the combination of GFLs and the lateral chain of heparan sulfate in the 
extracellular matrix (Hamilton et al., 1998). Despite the fact that the binding sites for the GFLs 
have been extensively studied, the gene regulation, mechanisms of secretion and the 
precursors leading to the activation of GFLs have not been fully elucidated (Golden et al., 
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1999). Similarly, the protease responsible for the breakdown and activation of the GFL 
precursor has yet to be revealed. Recent evidence has uncovered the biological activities for the 
precursor of secretory neurotrophic factors (Lee et al., 2001). The secreted NGF and BDNF are 
sheared outside the cell by serine protein kinases and selective matrix metalloproteinases. 
ProNGF has a high affinity for p75NTR, a receptor responsible for the apoptosis of neurons in 
culture media, and maintains mild activation of the pathway, accompanied by differentiation 
and survival of cells mediated by TrkA. Whether the proteolytic cleavage mediates the 
biological activities of the GFLs, and whether the functional GFLs are different from other 
ligands, are major areas of interest to current scholars. 
Of the 4 members of the GFLs, GDNF and NRTN were the first to be extracted. 
Subsequently, ARTN and PSPN were identified through basic data analysis and the use of 
homogeneous clones (Baloh et al., 2000). The GDNF gene for both humans and mice has 
been cloned and expressed in prokaryotic and eukaryotic vectors. The human GDNF gene is 
located on chromosome 5p13. 1-13. 3, and is composed of two exons and one intron. In 
humans and mice, two types of GDNF mRNA with different lengths exist: a large fragment 
of 633bp and small fragment of 555bp, encoding for polypeptides of GDNF precursors with 
211 amino acids and 185 amino acids, respectively. After the removal of 26 amino acids in 
the N terminal, the large fragment becomes smaller and the two fragments (large and small) 
are eventually transformed into polypeptides consisting of 134 amino acids (Trupp et al., 
1995). The mature protein of GDNF consists of 7 cysteine residues, and as such, 3 intrachain 
disulfide bonds are formed between the sites of amino acids 41 and 102, 68 and 131 and 72 
and 133. The cysteine residues in the side chain of amino acid 101 form interchain disulfide 
bonds, thus forming the structure of the homodimer of GDNF (Haniu et al., 1996). The 
structural features are quite similar to that of the TGF-ǃ family members. Two glycosylation 
sites lie in the polypeptide chain, which has a molecular weight of 20 kD. The molecular 
weight of the natural GDNF dimer, which contains a heparan biding site, is 40 - 45 kD. X-ray 
methods have demonstrated that the structure of rat GDNF contains two finger-like 
structures lying in the rostral and caudal parts. Additionally, the amino acids in the middle 
form a helical structure; two monomers are connected by a pair of disulfide bonds, and the 
four finger-like structures form a plane (Eigenbrot et al., 1997) (Figure 1). GDNF has 
conservation in evolution, as evidenced by the significant similarities between humans and 
mice in amino acid sequences in the mature proteins of GDNF (as high as 93%). Human 
GDNF, produced by genetic engineering, exerts activities on murine DA-ergic neurons. 
These lines of evidence indicate that GDNF has cross-species activity. 
 
 
Fig. 1. The molecular structure for the crystal monomer of GDNF.  
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The monomer structure of GDNF includes a central ǂ-spiral and ǃ-fold (A and B). The 
amino acids of A include two reverse and parallel ǃ-folds. The C-terminal of B contains four 
ǃ-folds. The dimer, with a reverse and parallel structure, presents a symmetrical receptor 
binding site. A and B are crucial binding sites for GFRǂ1. 
3.2 GDNF distribution and expression 
In mammalian brains, GDNF is mainly expressed in the target cells of DA-ergic neurons in 
the midbrain substantia nigra, such as granular cells in the corpora striatum, nucleus 
accumbens, thalamic nuclei, tuber olfactorium, hippocampus, cerebellum, callosal gyrus and 
olfactory bulb, where it acts as the original neurotrophic factor (Sonntag et al., 2005). In the 
kidneys and gastrointestinal tract, GDNF is expressed in media cells and smooth muscle 
cells, respectively. Additionally, GDNF induces the differentiation of neural crest cells and 
Wolffian ducts in intestinal neurons and renal ducts, respectively (Bohn et al., 2000). The 
peripheral expression of GDNF can also been seen in tissues innervated by sensory neurons 
(trigeminal ganglion, nodosal ganglion and dorsal root ganglion) and autonomic neurons. 
The distribution of GDNF in the human brain, which is identical to that in the rat brain, 
includes high expression in the caudate nucleus (innervated by the substantia nigra), low 
expression in the dorsal caudate putamen and no expression in the substantia nigra (Schaar 
et al., 1994). GDNF has also been reported to be expressed in the hippocampus, cortex and 
spinal cord (Springer et al., 1994). In general, the GDNF expression in peripheral organs is 
higher than that of neuronal tissues. 
3.3 The functions of GDNF 
In the CNS, GFLs maintain the survival and activity of DA-ergic neurons in the midbrain 
and motor neurons of the cornu anterius medullae spinalis. In addition, GDNF, NRTN and 
ARTN maintain the differentiation and survival of some peripheral neurons, such as 
sympathetic neurons, parasympathetic neurons, sensory neurons and neurons in the 
intestinal wall. Outside of the nervous system, GDNF plays vital roles in the processes of 
kidney development and spermatic production, along with many other processes in the 
body (Airaksinen & Saarma, 2002; Manié et al., 2001; Airaksinen et al., 1999). 
In the midbrain of adult animals, GDNF promotes the survival of DA-ergic neurons 
(Springer et al., 1994). Some scholars have proposed that GDNF plays an essential role in 
supporting the survival and maintenance of mature DA-ergic neurons (Pascual et al., 2008). 
Microinjection of 6-OHDA into the corpora striatum leads to the degeneration of DA-ergic 
neurons in the substantia nigra. This degeneration can be attenuated by pretreatment with 
GDNF in the substantia nigra, thus abrogating the injury induced by 6-OHDA and 
hindering the death of DA-ergic neurons. Other evidence has confirmed that GDNF 
promotes the regeneration of DA-ergic neurons after brain injury (Beck et al., 1995; Tomac et 
al., 1995; Hou et al., 1996), which correlates with the fact that GDNF promotes the 
differentiation of DA-ergic neurons after brain injury. For example, GDNF promotes 
increase of the cell body, prolongation of axons and an increase in dopamine synthesis. 
Additionally, studies have demonstrated that GDNF can selectively protect DA-ergic 
neurons against the neurotoxic effects exerted by methylamphetamine (Cass, 1996). Thus 
far, GDNF, as a potential therapeutic agent for PD, has been studied extensively (Azzouz et 
al., 2004; Eslamboli et al., 2005). Further research has demonstrated that GDNF can modulate 
neuronal excitability and transmitter release (Wang et al., 2003; Kobori et al., 2004). For 
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example, in vitro, GDNF can rapidly activate the MAPK signaling pathway after acting on 
midbrain DA-ergic neurons, and increase neuronal excitability (Yang et al., 2001). In 
addition, the GDNF signaling system can mediate the migration and chemotaxis of neurons 
(Tang et al., 1998). Some researchers have also demonstrated that GDNF can potentiate 
analgesia in neuropathic pain (Sakai et al., 2008). Further, GDNF plays critical roles in the 
neuronal development of sympathetic and motor neurons, and synapse formation in the 
hippocampus (Moore et al., 1996; Ledda et al., 2007). 
4. The signal pathway for GDNF activation 
4.1 GDNF receptors and structures 
4.1.1 GFRα 
The biological actions exerted by GDNF on cells must be mediated via trans-membrane signal 
transmission, i.e. membrane receptors, as GDNF is a secreted protein (Josso & di Clemente, 
1997). The receptor system for GFLs is divided into two parts. One part, a binding receptor, 
anchors to the cell surface via GPI and binds to GDNF directly. The identified GFLs include 
GFRǂ1, GFRǂ2, GFRǂ3 and GFRǂ4, each with its own binding receptor. For example, GDNF 
binds to GFRǂ1, NRTN binds to GFRǂ2, ARTN binds to GFRǂ3 and PSPN binds to GFRǂ4. 
The other part of the GFLs receptor system consists of the trans-membrane signal transduction 
receptor, RET, as well as a tyrosine kinase receptor. In the process of signal transduction, the 
members of the GDNF family share the same RET, but a distinct GFRǂ (Airaksinen et al., 1999). 
The homology between GFRǂ1 and GFRǂ2 is as high as 48%, and both are expressed in the 
neurons and tissues of the superior cervical ganglion and dorsal root ganglion (Baloh et al., 
1997). The expression of GFRǂ3 is strictly limited, and is not seen in the CNS (Widenfalk et al., 
1998). In contrast, GFRǂ1 and GFRǂ2 are widely expressed in the CNS and peripheral organs 
(Nomoto et al. 1998). The expression of GFRǂ4 has only been observed in avian cells (Saarma & 
Sariola, 1999). In addition, GFRǂ contains three corresponding cysteine-rich domains, with 
different lengths for three structural domains. The second domain binds to GFL, while the 
functions of the first and third domains are not clear. The first domain is not involved in the 
binding of RET and GFRǂ1, and is not expressed in GFRǂ4. 
4.1.2 RET 
RET is a trans-membrane tyrosine kinase receptor encoded by the oncogene Ret. Ret was 
first discovered in mice NIH/3T3 cells. Identical to other tyrosine kinase receptors, the RET 
protein is composed of an extracellular ligand-binding domain, a trans-membrane domain 
and an intracellular functional tyrosine kinase domain. The RET protein contains 21 exons 
and many spliceosomes, with four cadherin-like domains and a cysteine-rich domain. 
RET can be expressed as many sub-types based on the selective splicing of the primary Ret 
transcript (Tahira et al., 1990; Lorenzo et al., 1995). Two subtypes, RET9 and RET51, have 
been further studied, and the functional difference between the two is ascribed mainly to 
structural differences in the tails. The C-terminal end of RET9 contains nine amino acids, 
and the entire protein consists of 1072 amino acids. RET51 is longer than RET9, with a total 
of 1114 amino acids, including 51 amino acids in the tail. Both RET9 and RET51 have 
Tyr1062 in their C-terminal. Tyr1062 is phosphorylated during RET activation and 
anchoring of the receptor protein. Some researchers have demonstrated the regulation of 
lateral sequences in the C-terminal of Tyr 1062, which leads to different activities of the two 
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subtypes (Wong et al., 2005). Moreover, RET51 contains two tyrosine residues, Tyr 1090 and 
Tyr1096, which interact with SHC and GRB2, respectively (Lorenzo et al., 1997; Alberti et al., 
1998; Borrello et al., 2002). 
RET, a common signal transduction receptor for GFLs, mediates many signal pathways for 
GDNF and induces apoptosis (Bordeaux et al., 2000), and also inhibits tumor growth 
(Cañibano et al., 2007) when GDNF is absent. The mutation of Ret may lead to diseases with 
functional depletion. Activating mutations correlate with thyroid cancer and type-II familial 
polyendocrine adenomatosis. A deactivating mutation of Ret is the cause of Hirchsprung 
disease. In adult animals, the depletion of RET leads to the depletion of DA-ergic cells in the 
nigrostriatal system. This indicates that RET is a key factor in maintaining the nigrostriatal 
system. The degradation of RET occurs through Cb-1 ubiquitin ligase mediated receptor 
recruitment and ubiquitination in the proteasome pathway. 
4.1.3 NCAM 
In the CNS, the regions of expression of GFRǂ1 and RET are not identical, e.g. GFRǂ1, but 
not RET, is expressed in the cortex and hippocampus (Trupp et al., 1997; Glazner et al., 1998; 
Golden et al., 1998; Burazin & Gundlach, 1999; Golden et al., 1999). The absence of RET 
expression in these regions indicates the existence of RET-independent GDNF signal 
pathways. In 2003, Paratcha et al. demonstrated that GDNF has the ability to transmit 
signals through directly binding to NCAM (Paratcha et al., 2003). NCAM belongs to the cell 
adhesion molecule super family, and is encoded by a singular gene consisting of 26 exons 
(Lin et al., 1993). The selective splicing of the gene can produce almost 120 NCAM subtypes, 
three of which are named NCAM-120, NCAM-140 and NCAM-180. These three subtypes 
possess an identical extracellular N-terminus, which contains five immunoglobulin-like 
domains and two domains located on the cell surface that are homologous with type-III 
fibronectin. Both NCAM-140 and NCAM-180 are trans-membrane proteins possessing the 
same trans-membrane domains but different intracellular domains. NCAM-120 has no 
trans-membrane or intracellular domains, and anchors to the extracellular surface via GPI. 
NCAM-180 and NCAM-120 are expressed predominantly in fetal neurons and neuroglia, 
respectively, while NCAM-140 is expressed in both (Noble et al., 1985). Further research has 
demonstrated that the NCAM-140 subtype mediates the biological activities of GDNF. 
NCAM is not only involved in the adherence of cells, but also induces the intracellular 
signal transduction, and thus promotes axon growth and neuronal survival (Ditlevsen et al., 
2008) and inhibits the proliferation of astrocytes (Krushel et al., 1998). The action of GDNF 
on DA-ergic neurons in the midbrain can be attenuated by blocking the function of NACM 
using anti-NACM antibodies, indicating that GDNF is activated via an NACM-transmitted 
signaling pathway, even in brain regions that express RET (Chao et al., 2003). 
4.1.4 Integrins and N-cadherin 
Integrins are a family of cell surface receptors of cell adhesion molecules (CAMs). As a 
transmembrane glycoprotein, integrin is distributed on many types of cells, and can 
interact with extracellular ligands, the intracellular cystoskeleton and signal molecules to 
integrate the intra-with the extracellular environmental signals. Integrin is a heterodimer 
composed of an ǂ and a ǃ subunit, coupled by non-covalent bonds. Studies have indicated 
that integrin assembles some protein complexes via its ǃ subunit, which is responsible for 
the specificity of those proteins and the subsequent signals. FAK, a non-receptor tyrosine 
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kinase, plays an important role in this process. First, FAK binds to corresponding proteins 
in the C terminus and phosphorylates itself. The phosphorylated tyrosine then binds to an 
SH2 domain in Src. Next, many amino acids sites in FAK are phosphorylated by Src 
which initiates a series of signals. The extracellular segment of the ǂ subunit can bind to 
other proteins on the membrane, which would, in turn, bind to other SHCs. The 
phosphorylated tyrosines in SHC then bring the Grb2-SOS complex to the cell membrane 
and activate Ras. Integrins can bind to many extracellular matrix proteins, including 
laminin and fibronectin, which play vital roles in cell movement, adherence, 
synaptogenesis, proliferation, apoptosis, neural development and the inflammatory 
response (Chao et al., 2003; Anton et al., 1999). Some studies have indicated that GDNF is 
effective at increasing the expression of integrin ǂV, and the trans-membrane signal may 
include integrin ǃ1. Hence, integrin ǂV and integrin ǃ1 are thought to be candidate 
receptors for GDNF (Cao et al., 2008). 
N-cadherin, a member of the cadherin (cell adhesion molecule) super-family, is widely 
distributed in the CNS, and has a molecular weight of 130 kD. Cadherin super-family 
molecules are cell surface glucoproteins whose main functions include the regulation of 
calcium-mediated cell adhesion, cell polarity and morphogenesis, and involvement in the 
mechanisms underlying intercellular recognition and signal transduction. The recognition of 
N-cadherin is derived from its actions on cellular differentiation and growth in the CNS. N-
cadherin is a canonical trans-membrane protein, with five extracellular segments (cadherin 
domains) composed of 110 amino acid residues. Research has demonstrated that the entire 
extracellular segment of N-cadherin is very similar to that of RET (Anders et al., 2001) 
(Figure 2). The extracellular segments of N-cadherin can interact with catenin and other 
proteins, so as to regulate intracellular adhesion and recombination, and promote the 
survival and migration of cells. 
Accumulating evidence has demonstrated that both fibroblast growth factor (FGF) and 
epidermal growth factor (EGF) can exert their actions by binding to N-cadherin via their 
receptors. Recently, our studies (using plasmid construction and cell transfection) have 
demonstrated that inhibition of the biological functions of N-cadherin may influence the 
protective effects exerted by GDNF upon DA-ergic neurons. At the same time, we 
discovered that GDNF can bind to N-cadherin or RET directly (data not shown). Further 
studies should be undertaken to determine whether GDNF activation of downstream signal 
pathways is dependent on the interaction of its receptor and N-cadherin (a process that is 
identical to FGF and EGF).     
The distance from the neuronal adherent proteins’ domain to the cell membrane is similar to 
that of RET. The encoding of the RET residues is consistent with the naïve RET molecule. 
The black solid line indicates the inserted sequence for the RET extracellular segment. The 
black solid circle indicates coherent calcium binding sites. CD = binding site for cadherin, 
TK = tyrosine kinase, Cys = cysteine-rich domain, Cyt = cytoplasmic domain (adapted from 
Anders et al.,,2001) 
4.1.5 Heparan sulfate glycosaminoglycans 
Aside from RET and GFRǂ1, heparan sulfate proteoglycans, including syndecan and 
glypican, are essential in mediating the signal pathway of GDNF (Barnett et al., 2002). 
Bespalov et al. demonstrated that syndecan, exerts its function via binding to heparan sulfate 
with high affinity (Bespalov et al., 2011).  
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Fig. 2. The comparison of human neuronal adherent proteins and the RET extracellular 
segment.  
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GDNF mediates axonal growth and promotes neuronal migration via binding to syndecan 
3. Of course, syndecan 3 may mediate the GFL signaling pathway, or may submit GFLs to 
the RET receptor pathway. With regard to other receptors, activation of the MET tyrosine 
kinase receptor by heparan sulfate proteoglycans is essential for the NCAM mediated 
GDNF pathway (Sariola & Saarma, 2003). The effects of heparan sulfate proteoglycans on 
the integrin ǂV/ǃ1 and N-cadherin mediated GDNF signal pathway is under 
investigation. 
The paucity of heparan sulfate proteoglycans may inhibit GDNF-dependent RET 
phosphorylation, GDNF mediated axon growth and differentiation of endothelial cells 
(Barnett et al., 2002). Substantial evidence in mice indicates that a lack of syndecan or GDNF 
may lead to a decrease in GABA-releasing neurons, which implies that the two molecules 
are involved in cortex development.  
4.1.6 Heat shock protein 27 
Heat shock protein 27 (HSP27) is a protein with high conservation that is selectively 
synthesized after being stimulated. It resides ubiquitously in the cell membrane, cytoplasm 
and nucleus of all prokaryotes and eukaryotes. HSP27 is involved in maintaining 
microfilaments, signal transduction of cytokines, maintaining the integrity of the cell 
membrane under stimuli and protection of cells against some stress injuries (Nakamoto & 
Vígh L, 2007). In 2009, Hong Z et al. discovered that 92 proteins were altered under the 
action of GDNF; among the altered proteins, the phosphorylation of HSP27 significantly 
increased, accompanied by nuclear translocation. The GDNF induced axonal growth of PC 
12 cells is significantly inhibited by interference of HSP27 mRNA, which implies that many 
proteins are involved in GDNF-mediated neuronal differentiation of DA-ergic neurons. 
HSP27 is a novel signaling molecule involved in GDNF-mediated axon growth of DA-ergic 
neurons (Hong et al., 2009).  
4.2 RET-dependent signaling pathway 
GFRǂ1 and RET are expressed in the DA-ergic neurons of the substantia nigra and ventral 
tegmental area, as well as in the ǂ-motor neurons of the ventral spine and motor nuclei in 
the brain stem, such as the hypoglossal nucleus, facial nucleus, nuclei of the trigeminal 
nerve and the nucleus nervi abducentis (Glazner et al., 1998). RET is mainly located in non-
lipid regions where GDNF action is absent (Paratcha et al., 2001). 
GDNF activates RET via two pathways, in cis and in trans. When expressed in the same cell, 
the combination of GFRǂ1-RET is mediated by a cis signaling system (Yu et al., 1998; 
Paratcha et al., 2001), delineated as: (1) activation of the cis system, (2) GDNF binds to GPI-
anchored GFRǂ1 on the membrane, (3) c-RET is recruited and activated, which is 
independent of tyrosine kinase activity. On the other hand, when GFRǂ1 is dissoluble, its 
binding to GFRǂ1-RET via a trans signaling system is delineated as: (1) GDNF and 
dissoluble GFRǂ1 (sGFRǂ1) are released from consecutive cells, (2) activation of 
extracellular c-RET, (3) the activated receptors couple and phosphorylate SHC, (4) c-RET is 
recruited to the membrane via activation of its tyrosine kinase and phosphorylation of Tyr-
1062. Compared with the cis system, the recruitment of RET to the membrane mediated by 
dissoluble GFRǂ1 is delayed and persistent, and is dependent on the activation of domains 
of the RET self-kinase (Yu et al., 1998; Paratcha et al., 2001). 
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RET is recruited to the membrane and binds to GDNF-GFRǂ1 via the two pathways 
mentioned above. After recruitment to the membrane, a dimer is formed, which is 
followed by self-phosphorylation of RET intracellular segments (rendered as tyrosine 
kinase activity), recruitment of downstream signal molecules and activation of several 
intracellular signal pathways via a series of enzymatic reactions (Airaksinen et al., 1999). 
In this way, cell survival, differentiation, proliferation, migration and chemotaxis are 
regulated. The binding site of SHC receptor proteins, tyrosine 1062, plays vital roles in 
the activated intracellular signal cascade reactions. After binding to the intracellular 
tyrosine of RET, SHC forms a complex with the GAB1/2 receptor protein and 
GRB2/SOS, and induces activation of the PI3K/Akt and RAS/ERK signaling pathways, 
respectively. After combination of tyrosine 1096 and GRB2, GAB1/2 binds to the p85 
subunit of PI3K, causing the activation of PI3K (Airaksinen & Saarma, 2002). GDNF 
induces the formation of neuronal lamellar parapodia, which is related to the formation 
of the neural axis (Van Weering & Bos, 1997) and DA-ergic differentiation in vitro (Pong 
et al., 1998). Jun N-terminal Kinase (JNK) is activated by Rhc/Ras-related small 
molecules (Chiariello et al., 1998), such as GTPase and CDC42. As key regulatory factors 
for survival of neurotrophin-dependent neurons, JNK and PI3K/Akt may be involved in 
the trophic action of GDNF (Kaplan & Miller, 1997). Tyrosine 981 binds to Src, and 
activated p60Src is a key factor for GFL-induced signal cascade reactions. The GDNF 
signaling pathway regulates axonal epitaxy, distribution of ureters and neural survival 
(Airaksinen & Saarma, 2002). After binding to tyrosine 1015, PLC is activated and 
hydrolyzes the second messenger produced by IP3, which increases intracellular calcium 
and activates multi-signal transmissions such as gene expression. The Ras-MAPK and 
PI3K/Akt signal pathways are involved in DA-ergic neurons, and GDNF activates 
cAMP/PKA/CREB in brain neurons in the fetus. The activation of Src kinase and PLC is 
involved in sensory neurons (Sariola & Saarma, 2003) (Figure 3). RET possesses  
other tyrosine residues, including Tyr687, Tyr826 and Tyr 1029, which correlate with 
GFL binding. The mechanisms involved in signal transmission, however, are still 
unclear. 
RET, but not GFR, is expressed in the cerebellum, olfactory tubercles and nuclei in  
the hypothalamus. This could be explained by the hypothesis that the actions of GFR  
are independent on RET, and GFR is only active in trans-formation (Saarma & Sariola, 
1999). 
The extracellular domain of RET contains four cadherin-like structures and a cysteine-rich 
region. Phosphorylated Y1062 is the binding site for several proteins, which subsequently 
activates the RAS/ERK, JNK and PI3K/Akt signal pathways via binding to SHC, FRS2, 
IRS1/2, Dok1-5 and Enigma. Phosphorylated Y905, Y981, Y1015 and 1096 bind to GRB7/10, 
Src, PLCǄ and GRB2, respectively, and mediate a series of signal pathways. (Adapted from 
Wells & Santoro, 2009). 
4.3 RET-independent signaling pathway 
In spite of the vital roles played by RET-mediated signaling pathways, the GFRǂ1-RET 
signal system is not an essential pathway for neuronal development (demonstrated in 
knockout mice). Recently, a series of studies has demonstrated that GDNF may exert its 
biological actions via RET-independent signaling pathways. 
www.intechopen.com
 Actions of GDNF on Midbrain Dopaminergic Neurons: The Signaling Pathway 
 
203 
 
Fig. 3. The structure of RET and its signal pathway mediation.  
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4.3.1 GDNF and Src 
As mentioned previously, the activation of Src family kinases mediated by GDNF is 
independent of RET. Src family kinases are non-receptor type tyrosine kinases. The Src 
family is divided into three sub-families: the SrcA sub-family, consisting of Src, Yes, Fyn, 
and Fgr; the SrcB sub-family, consisting mainly of Lck, Hck, Blk, and Lyn; and another sub-
family composed of Frk. SrcA and SrcB sub-families are specific to vertebrates. The 
activation of Src family kinases is closely related to a series of biological functions, such as 
cell division, migration, apoptosis and differentiation. Poteryaev et al. demonstrated that 
GDNF activates Src-family tyrosine kinases, after binding to the GFRǂ1-GPI complex, in 
mice DRG neurons (RET tyrosine kinase paucity); phosphorylation of MAPK kinase, PLC2Ǆ 
and CREB ensue, and induce the third messenger IP3 to increase calcium concentration, 
eventually promoting cell survival and Fos expression (Paratcha & Ibáñez, 2002). Popsueva 
et al. also demonstrated that GDNF can promote the differentiation of MDCK cells (GFRǂ1 
positive and RET negative) via activation of the Src family kinases (Popsueva et al., 2003). 
Trupp also demonstrated, using an immortalized neuronal precursor cell line, RN33B (high 
expression of GFRǂ1 and no expression of RET), that GDNF does not activate the Ras/ERK 
signaling pathway, in these cells; instead GDNF induces the activation of Src family kinases, 
rapid phosphorylation of CREB and up-regulation of c-fos mRNA (Trupp et al., 1999). This 
study provides additional evidence supporting the notion that the functions of GDNF are 
independent of RET.   
4.3.2 GDNF and MET 
The differential expression models for GFR and RET indicate that: (1) GFR functions via signal 
transduction pathways that do not involve RET, and (2) other GDNF ligands (binding to GFR) 
are involved. MET is a hepatocyte growth factor receptor (HGFR) that is normally expressed 
in epithelium-derived cells. The expression of hepatocyte growth factor is limited in 
desmohemoblast-derived cells. The primary precursor proteins of MET are cleaved to produce 
ǂ and ǃ subunits. The mature receptor is formed via a disulfide bond, and plays preliminary 
roles in embryonic development and wound healing. After stimulating hepatocyte growth 
factor, MET induces several biological reactions. In many RET-absent but GFRǂ1-rich cells, 
GDNF induces the phosphorylation of MET, and then activates the Src family kinases. This 
provides impetus for research on a RET-independent GDNF signaling system. The RET-
independent activation of Src and MET, induced by GDNF, may be regulated by heparan 
sulfate and NCAM. However, in vivo immunoprecipitation studies have demonstrated that 
MET does not bind to GDNF, implying an uncertain role for GDNF-induced MET activation. 
4.3.3 GDNF and NCAM 
The GFRǂ receptor is expressed more widely than RET in many regions of the nervous 
system, especially the procerebrum, cortex and internal ear (Trupp et al., 1997; Kokaia et al., 
1999), indicating that the signal transduction in neurons and glials, and GLF-protein binding 
may not always be dependent on RET. Other studies demonstrated that GFRǂ1, but not 
RET, is expressed in the RN33B cell line, and the signal pathway induced by GDNF overlaps 
with that induced by NCAM. In 2003, Paratcha et al. demonstrated that NCAM may mediate 
actions via RET-independent trans-membrane signaling. Further studies demonstrated that 
NCAM is involved in the promotion effects, engendered by GDNF, affecting the survival of 
DA-ergic neurons (Paratcha et al., 2003). When GFRǂ is absent, the binding between GFLs 
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and NCAM is low. In contrast, GDNF binds to NCAM140 closely when GFRǂ1 binds to 
NCAM; this leads to the phosphorylation of Fyn, a molecule conjugated to the intracellular 
segments of NCAM, followed by phosphorylation of FAK, and eventually activation of the 
MAPK signal pathway via normal signal transduction. Interestingly, the combination of 
GFRǂ1 and NCAM may downregulate NCAM-mediated cellular adherence when GDNF is 
absent (Cao et al., 2008). This regulation is indicative of the independent roles played by 
GFRǂ1-NCAM and the GDNF-GFRǂ1-NCAM signaling pathway. In the RET-independent 
model, GDNF stimulates the migration of neurilemma cells and the growth of synapses. 
This finding indicates that the GFRǂ protein, GFLs, or their combination with NCAM, 
activates distinct pathways to regulate differential signal pathways. 
4.3.4 GDNF and integrins 
GDNF is a crucial neurotrophic factor for DA-ergic neurons. Transmembrane signal 
transduction is mediated by a special receptor system, which includes GFRǂ, RET, and 
NCAM140. Thus far, we have identified that another transmembrane cell adhesion 
molecule, integrin (a heterodimer consisting of ǂ and ǃ subunits), can regulate the signal 
transduction of GDNF. Some studies have demonstrated that chronic injection of GDNF into 
the substantia nigra increases the expression of integrin ǂV and NCAM (Chao et al., 2003). 
This implies that GDNF exerts special effects on the increase of integrin ǂV expression, and 
that integrin ǂV may be a selective receptor for functional GDNF. 
Under the influence of GDNF, the combination of phosphorylated SHC and intracellular 
integrin ǃ1 increases. Data from co-immunoprecipitation demonstrate that integrin ǃ1 and 
GFRǂ1 form a complex. Additionally, phosphorylation of SHC in the cytoplasmic domain of 
integrin ǃ1 was shown to increase after stimulation with GDNF. Other data from molecular 
models demonstrated the presence of four hydrogen bonds between integrin ǃ1 and GFRǂ1. 
These data indicate that integrin ǃ1 may be involved in the transmembrane signaling of 
GDNF, and that integrin ǃ1 may even be a selective signal receptor for GDNF (Cao et al., 2008).  
4.3.5 GDNF and N-cadherin 
N-cadherin is a transmembrane adhesion protein, whose cytoplasmic region can interact with 
various intracellular proteins (Drees et al., 2005; Reynolds, 2007). When its extracellular domain 
binds a ligand, the intracellular domain of N-cadherin can activate the PI3K/Akt and 
Ras/Raf/MAPK signaling pathways (Hulit et al., 2007). It is well-known that the structural 
and functional characteristics of N-cadherin are somewhat similar to that of NCAM and 
integrin ǃ1, and that it mediates not only adherence, but also signal transduction. In addition, 
the binding site for the extracellular domains of RET and the GDNF/GFRǂ1 complex, is a 
cadherin-like domain. Our previous studies have demonstrated that N-cadherin can also bind 
to GDNF, and the phosphorylation of the N-cadherin intracellular domain (Tyr860) is 
mediated by GDNF. Further studies, using gene silencing and immunoblotting, have 
demonstrated that GDNF activates the intracellular PI3K/Akt signaling pathway via N-
cadherin, thus protecting DA-ergic neurons. Results from studies, using flow cytometry and 
Hoechst 33258 staining, indicate that GDNF interferes with the expression of N-cadherin, and 
that the apoptosis of injured DA-ergic neurons increases. Additional results from 
immunoblotting indicate, under the same conditions, that phosphorylated Akt, but not total 
Akt, decreases in the cytoplasm. Results from immunohistochemistry indicate a decrease in 
total N-cadherin, phosphorylated N-cadherin (Tyr860) and phosphorylated Akt, however, 
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total Akt does not change. Finally, through immunoblotting it was discovered that the levels of 
phosphorylated N-cadherin (Tyr860) and phosphorylated Akt are dose-dependent on GDNF, 
and that the peak levels of both occur at 50 ng/ml (in vitro) and 13 ng/μl (in vivo) of GDNF. 
The levels of phosphorylated N-cadherin (Tyr860) and phosphorylated Akt are also time-
dependent, and the peak levels of both occur at 15 min (in vitro) and 30 min (in vivo) after 
GDNF actions. Statistical analyses show that the two phosphorylations are positively related. 
Thus, it may be concluded that GDNF activates the PI3K/Akt pathway via N-cadherin to 
protect DA-ergic neurons. 
5. Effects of membrane lipid rafts on GDNF actions 
Tiny regions in cell membrane exist that differ in composition from other parts of the 
membrane. In these regions, the extracellular lipids contain rich sphingolipids and 
cholesterol molecules, which gather and form a mobile platform of fluid double-lipids, i.e. 
lipid raft. The main components of lipid rafts include GPI-coupled proteins 
(extramembrane), trans-membrane tyrosine kinases (intermembrane) and two Src family 
tyrosine kinases (intramembrane) (Simons & Ikonen, 1997). The lipid raft is an essential 
structure in the membrane for signal transduction, and plays a vital role in cell adherence, 
axon guidance and synaptic transmission (Paratcha & Ibáñez, 2002). 
Substantial studies have focused on GDNF and its receptors, but the studies on the function 
of lipid rafts and the relationship between GDNF and its receptors are few and far between. 
To determine whether receptor-mediated GDNF is dependent on the functional lipid rafts, 
we investigated four transmembrane proteins in the lipid rafts (RET, NCAM140, integrin ǃ1 
and N-cadherin) and their involvement in mediating GDNF signal pathways. To this end, 
the binding of these proteins and GDNF was analyzed, using co-immunoprecipitation, 
based on the integrity of the membrane lipid rafts. The results demonstrated that all 
proteins bound to GDNF when the lipid raft was complete, and only RET and N-cadherin 
bound to GDNF when the lipid raft was not complete. In addition, extraction tests for the 
membrane lipid rafts have demonstrated that RET and NCAM, but not N-cadherin and 
integrin ǃ1, may be shifted to the lipid rafts by GDNF. This series of tests indicates the 
importance of lipid rafts in mediating the interaction of GDNF with its receptors (Figure 4). 
RET can mediate the protective actions exerted by GDNF upon DA-ergic neurons (Trupp et 
al., 1996; Durbec et al., 1996). After GDNF stimulation, RET induces multiple signals to 
mediate the signal pathways of GDNF via two models (intra-lipid raft and extra-lipid raft) 
(Tansey et al., 2000). Membrane lipid rafts are the basis for the shift and functional activation 
of RET (Poteryaev et al., 1999). Activated RET influences different downstream targets in 
lipid rafts. The RET activated extra-raft preferentially binds to SHC, and the RET activated 
intra-raft binds preferentially to FRS2, thus mediating a series of signal pathways. The 
membrane lipid rafts provide abundant micro-environments for the binding of RET and 
kinases/receptor proteins in the raft, and is involved in the GFL signaling pathway. For 
example, Src family kinases, as proteins in the raft, mediate a series of functions of GDNF 
signal transduction, after binding to activated RET. In the lipid rafts rich in GFRǂ1 and Src, 
GDNF activates Src via a GFRǂ1 mediated pathway (Tansey et al., 2000). Furthermore, the 
location of RET on the lipid raft enhances its binding to Src, whose activation is essential for 
GDNF mediated promotion of survival (Encinas et al., 2001). In a lipid raft, RET cannot be 
degraded by proteases, and this protective effect may be related to its downstream actions 
of regulating receptor functions (Pierchala et al., 2006). 
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Fig. 4. A membrane lipid raft is an ultrastructure rich in cholesterol and 
phosphosphingolipids.  
NCAM can function as a receptor of GDNF signal transduction (Sjöstrand et al., 2007; 
Sjöstrand & Ibáñez, 2008). Under the influence of GDNF, NCAM140 binds to Fyn and is 
recruited to lipid rafts, followed by stimulation of the migration of Schwann cells and 
promotion of neuronal axonal growth (Paratcha et al., 2003). In membrane lipid rafts, the 
binding of NCAM and Fyn leads to recruitment of FAK and the activation of the Ras-Raf-
ERK1/2 pathway (Beggs et al., 1997; Niethammer et al., 2002).  
Integrin ǃ1 is a transmembrane cell adhesion molecule, which is expressed in DA-ergic 
neurons in the substantia nigra of adult mice (Cao et al., 2008). Inhibitory antibodies can 
counteract the effects of GDNF on the promotion of survival and growth of DA-ergic 
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neurons (Chao et al., 2003). Some reports have demonstrated that the membrane lipid rafts 
provide a perfect environment for the activation of integrins, mediated by growth factors, in 
the system of survival for oligodendrocytes. The shift of activated integrin to membrane 
lipid rafts is an important cue, which provides rationale for the actions of functional T cells 
and the basis for the study of integrin in other cells (Leitinger & Hogg, 2002).  
N-cadherin, a calcium dependent cell adhesion molecule similar to NCAM140 and integrin 
ǃ1, is a trans-membrane protein that mediates the axonal growth of astrocytes and Schwann 
cells. As mentioned above, the intracellular domain of N-cadherin is similar to the extra-
domain of RET. Additionally, N-cadherin can activate the PI3K/Akt and Ras/Raf/MAPK 
signal pathways (et al.,) (73), which provides the rationale for further delving into GDNF and 
its function. 
It is closely related to signal transduction in the membrane and provides a platform for 
anchoring proteins. A: GFRǂ1 and integrin ǃ1 integrate into the membrane lipid raft of DA-
ergic neurons, but RET, N-cadherin, and NCAM-140 are outside of the raft. B: A GDNF 
dimer combines with GFRǂ1 and forms a GDNF-GFRǂ1 complex, which binds to RET and 
gathers in the membrane lipid raft. The combination of the GDNF dimer and NCAM dimer 
requires another substance. N-cadherin and integrin do not gather in the membrane lipid 
raft, but N-cadherin can bind to GDNF outside of the raft. 
6. GDNF treatment in Parkinson’s disease 
The degeneration of DA-ergic neurons in the substantia nigra of the midbrain is the main 
pathological characteristic of PD. Based on this characteristic, the most predominant 
therapeutic strategies are to administer DOPA agents to supply dopamine to the brain, or to 
employ dopamine agonists to activate the DA-receptor directly. However, the efficacies of 
these drugs tend to wane because the residual DA-ergic neurons decrease during the 
progression of PD. In 1993, GDNF, as a growth factor that promotes the survival and growth 
of DA-ergic neurons in the midbrain, was extracted and qualified (Lin et al., 1993). Early 
studies demonstrated that GDNF elevates the affinity of neurons to DA, increases the 
uptake of DA and the expression of tyrosine hydroxylase and promotes the growth of 
neurapophysis in cultured midbrain DA-ergic neurons. In addition, GDNF was 
demonstrated to act as neurotrophic factor in spinal motor neurons (Henderson et al., 1994) 
and noradrenergic neurons (Arenas et al., 1995) in the CNS. Further, GDNF was found to 
maintain a low level in PD patients and in elder rodents (Yurek & Fletcher-Turner, 2000; 
Jenner and Olanow, 1998). Thus, this neurotrophic factor is viewed as a potential treatment 
for neurodegenerative disease. 
In cultured embryonic DA-ergic neurons, the paucity of GDNF initiates a novel non-classical 
death pathway in which the mitochondria does not release cytochrome to the cytoplasm, 
Bax is not activated and over-expressed Bcl-xL does not inhibit death. However, death is 
inhibited by the caspase inhibitor BAF, and mutants of caspase-9, caspase-3 and caspase-7, 
indicating that caspases are essential for the process. Another study demonstrated that in 
the MLK-c-Jun pathway, caspase-2 and caspase-7 are essential for GDNF-paucity-induced 
death. In neuroblastoma cells, the GDNF response is similar. 
Based on this principle, researchers have adopted different models to supply GDNF in PD 
animal models. The results demonstrated that GDNF inhibits the variation of Bcl-2 and Bax, 
up-regulates Bcl-XL, inhibits the combination of CYT-C and Apaf-1 as well as the activity of 
caspase-3 (Ghribi et al., 2001) reverses the death of DA-ergic neurons induced by 
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neurotoxins and stimulates functional recovery. In the presence of Aǃ peptide, GDNF can 
inhibit Aǃ neurotoxin via blocking the activation of gad153, JNK and ERK induced by ER 
stress, and promote cell survival. In granular cells of the cerebellum, GDNF inhibits the 
activation of p38-MAPK via PI3K, and prevents the injury induced by TGF-ǃ in the 
protoplasmic membrane (Subramaniam et al., 2008). 
The summary of research progress on different GDNF supplementation methods is as 
follows: 
Direct injection of GDNF: Some studies have demonstrated that injection of GDNF into the 
substantia nigra only decreases the apoptosis of DA-ergic neurons, but injection into the 
striatum corpora repairs the neuronal process of TH-positive neurons and improves the PD 
symptoms (Bohn et al., 2000). Injection of GDNF into the striatum corpora can decrease the 
death rate of DA-ergic neurons up to 60%, as well as increase the ispilateral TH-positive 
immunoreactivity and synaptic growth in the nigrostriatal system. Additionally, injection of 
GDNF into the striatum corpora can increase the amount, volume and synaptic length of 
DA-ergic neurons as well as the uptake of dopamine. 
Injection of GDNF via virus vehicle: This method can transfer the neurotrophic factors into 
the CNS (Figure 5). In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) animal models, 
a lentivirus encoding GDNF was injected into the caudate nucleus, putamen and substantia 
nigra; a lentivirus encoding for the ǃ-galactosidase enzyme was injected in the control 
group. Three months later, the PD system scores in the test groups were improved 
compared to that of the control group (Kordower et al., 2000). Bowenkamp et al. used 6-
OHDA animal models and obtained similar results (Bowenkamp et al., 1996). These findings 
indicate that GDNF plays a positive role in neuronal reconditioning and synaptic growth in 
the substantia nigra. However, over-expressed GDNF may also play a negative role in PD 
treatment. Eslamboli et al. reported that high levels of GDNF expression altered bilateral DA 
transport and synthesis, and produced toxic or adverse effects (Eslamboli et al., 2003; 
Eslamboli et al., 2005). Thus, low and sustained expression seems to be most prudent. In 
Huntington's disease, the repeated gene amplification of the huntingtin protein leads to 
neurological disorders, which can be attenuated by adenovirus-vehicle mediated GDNF 
expression. 
Injection of GDNF via cell mediation: Researchers are searching for other efficacious ways to 
import GDNF. For example, the BHK-21 cell, transformed by genetic engineering, can 
persistently express GDNF in neural stem cells (Behrstock & Svendsen, 2004). Here, we 
introduce a method of delivering GDNF termed encapsulated cell delivery (ECD). This 
method requires a catheter-like device with a diameter of no more than 1 mm, which is used 
to inject agents into the striatum corpora. A mobile device, made up of a hollow fiber 
membrane (< 1.5 cm), is used to control the diffusion of nutrients and injected GDNF. Cell 
lines of high quality are selected via this fiber membrane. In the process, the membrane is a 
barrier preventing immunological rejection of allogenic cells. 
GDNF permeable to the blood-brain barrier: Recently, a novel GDNF was developed. It is a 
fusion protein formed by the combination of GDNF and cell perforin mediated by the trans-
activator of the HIV virus. Diez et al. demonstrated, in the mouse PD model (i.p. injection), 
that Tat-GDNF could cross the blood-brain barrier and enter into the nigrostriatal system 
(Dietz et al., 2006). Unfortunately, Tat -GDNF could not protect injured DA-ergic neurons or 
improve PD symptoms in MPTP models. 
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1. Immature myogenous cells are infected by improved GDNF-carrier genes. 
2. The infected myogenous cells are injected into muscle in amyotrophic lateral sclerosis (ALS) mice 
3. The infected cells mix with myogenous cells, and produce and secrete GDNF, which is absorbed 
by nerve fibers. 
4. GDNF is transferred into the body of neurons and maintains the survival of the cells.  
(Figure source: www.epfl.ch) 
Fig. 5. Injection of GDNF into the CNS to transfer neurotrophic factors via virus-vehicle. 
Results from animal models provide invaluable information for clinical research. In 2002, 
Steven Gill and colleagues injected GDNF directly into the brain of PD patients, which 
significantly attenuated the PD symptoms (Gill et al., 2003). The purpose of this Phase I clinic 
trial was to evaluate the safety of GDNF injections. Previous data, based on animal models, 
showed that GDNF can prolong the survival time of DA-ergic neurons and enhance their 
functions. In this study, researchers pumped GDNF into the striatum corpora of five PD 
patients at dose of 40 mg/d, for 18 months. These researchers believed that the cells closest 
to tip of the catheter absorbed the GDNF first. After permeating the brain tissues, GDNF 
reached the DA-ergic cells. The results demonstrated that the symptoms were attenuated, 
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the motor functions were elevated by 39%, the quality of life was improved and daily 
activities were increased by 61%; no adverse effects were reported up to one year later. 
Results from PET scans demonstrated that GDNF enhanced dopamine in brain. This therapy 
also attenuated L-dopa induced tremors. Unfortunately, in 2004, Amgen conducted a larger-
scale trial, and GDNF did not exert effects as expected. Further, the company expressed 
concern over the safety of GDNF. After that, the direct application of GDNF was all but 
abandoned. However, exploration into mechanisms of action of GDNF is an alternative 
avenue that may aid in the development of new therapies for PD treatment. 
7. Conclusion 
After the identification of GDNF, three other family members (NTN, PSP and ART) were 
identified, and as further studies are undertaken, more family members may be uncovered. 
The receptors of these factors are composed of two parts: the GDNF family receptor and the 
transmembrane tyrosine kinase RET. The GPI-coupled GFR determines their specific signal 
transduction. 
Initially, researchers assumed that only one signal pathway for GDNF existed: via GFRǂ1/2, 
anchored by receptor tyrosine kinase RET and glycosyl-phosphatidyl inositol. In 2003, in 
vitro studies demonstrated that the adhesion molecule NCAM was a receptor for GFLs that 
was independent of RET signaling. Recently, studies have indicated that integrin ǂV/ǃ1 and 
N-cadherin may also be selective receptors for GDNF. As more evidence comes to light, it is 
evident that the signal pathway for GDNF protection of DA-ergic neurons is a complex one. 
In DA-ergic neurons, GDNF activated Ras-MAPK and PI3K/Akt signaling pathways play 
vital roles in neuronal survival and axon growth. Present studies indicate that NCAM, a 
new GFI receptor, is also involved in the signaling pathways of GDNF-GFRǂ1-MET and 
NGF-TrkA-RET, which also makes the biological characteristics of GDNF complex.  
Some progress has been made in therapeutic trials for neuronal degenerative diseases based 
on the neurotrophic actions of GDNF. Repeated, direct injection of GDNF is especially 
valuable for treating myeleterosis such as amyotrophic lateral sclerosis (ALS). Because of the 
features of the blood-brain barrier and brain tissues, direct injections of GDNF to treat PD 
and other neurodegenerative diseases have limited use. Thus, direct GDNF gene injection 
mediated by vehicle or transgenic cellular transplant is a promising alternative. Currently, 
the challenge lies in the development of a safe, novel vehicle for the delivery of genes that 
can be specially expressed in tissues, can induce gene expression and can replace the virus 
vehicle. 
In the management of PD, the application of drugs with low molecular weights is another 
choice for recombining neurotrophic factors. Other GFLs may be of potential value for 
treatment. Present studies demonstrate that, in murine PD models, PSPN, which is 
transferred into brains via neuronal stem cells, exerts effects as well as GDNF, on the 
survival of DA-ergic neurons in the midbrain (Akerud et al., 2002). As we know, the 
expression of GFRǂ4, which is the receptor of PSPN, is more limited than that of GFRǂ1, the 
receptor of GDNF. Thus, we can propose that, even if high concentrations of PSPN are used, 
the adverse effects may be fewer than using GDNF (Lindahl et al., 2000). The next challenge 
is to identify novel drugs, with low molecular weights and natural neurotrophic properties, 
to influence intracellular signal transduction. These explorations should be based on the 
comprehensive recognition of GFLs and the 3D structure of its receptor, as well as 
molecules, cells and disease. 
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